Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 8/20 | 0.40 |
| ▸ | CA2 | P00918 | 8/20 | 0.40 |
| ▸ | CA9 | Q16790 | 7/20 | 0.40 |
| ▸ | CA12 | O43570 | 3/20 | 0.40 |
| ▸ | CA7 | P43166 | 3/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.40 |
| ▸ | CA3 | P07451 | 2/20 | 0.40 |
| ▸ | CA4 | P22748 | 2/20 | 0.40 |
| ▸ | CA6 | P23280 | 2/20 | 0.40 |
| ▸ | CA5A | P35218 | 2/20 | 0.40 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.40 |
| ▸ | RECQL | P46063 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL391506 | 1.00 | DNM1 (0.48) | DNM1CA1CA2CA9CA12 | |
| SCHEMBL931394 | 1.00 | DNM1 (0.48) | DNM1CA1CA2CA9CA12 | |
| SCHEMBL887114 | 1.00 | DNM1 (0.48) | DNM1CA1CA2CA9CA12 | |
| SCHEMBL246013 | 1.00 | DNM1 (0.48) | DNM1CA1CA2CA9CA12 | |
| SCHEMBL28795866 | 0.96 | DNM1 (0.45) | DNM1CA1CA2CA9CA12 | |
| SCHEMBL27515670 | 0.96 | DNM1 (0.45) | DNM1CA1CA2CA9CA12 | |
| SCHEMBL26629020 | 0.94 | DNM1 (0.44) | DNM1CA1CA2CA9CA12 | |
| SCHEMBL9302688 | 0.90 | ADRB2 (0.38) | DNM1CA1CA2CA9TSHR | |
| SCHEMBL2701156 | 0.88 | ALDH1A1 (0.51) | LPAR1LPAR3LPAR2 | |
| SCHEMBL27503005 | 0.86 | ADRB2 (0.35) | DNM1CA1CA2TSHRHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 481 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118251497-A | Lipid compositions comprising peptide-lipid conjugates | 阿克丘勒斯治疗公司 | 2024-06-25 | — | — | CN | claimed |
| CN-118201639-A | Peptide-lipid conjugates | 阿克丘勒斯治疗公司 | 2024-06-14 | — | — | CN | claimed |
| WO-2024119017-A1 | SYNTHETIC SINGLE STRANDED NUCLEIC ACID COMPOSITIONS AND METHODS THEREOF | GENERATION BIO CO. (US) | 2024-06-06 | — | — | WO | claimed |
| EP-4334455-A1 | LIPID COMPOSITIONS COMPRISING PEPTIDE-LIPID CONJUGATES | Arcturus Therapeutics, Inc. (US) | 2024-03-13 | — | — | EP | claimed |
| EP-4305051-A1 | CHIMERIC PROTEINS IN AUTOIMMUNITY | Shattuck Labs, Inc. (US) | 2024-01-17 | — | — | EP | claimed |
| WO-2023077156-A1 | MODIFIED MRNA THERAPEUTICS | SHATTUCK LABS, INC. (US) | 2023-05-04 | — | — | WO | claimed |
| EP-3558271-A1 | METHODS FOR AMELIORATING INFUSION REACTIONS | Arbutus Biopharma Corporation (CA) | 2019-10-30 | — | — | EP | claimed |
| EP-3500294-A1 | ANTI-PD-1 ANTIBODIES, OR FRAGMENTS THEREOF, FOR TREATING HEPATITIS B | Arbutus Biopharma Corporation (CA) | 2019-06-26 | — | — | EP | claimed |
| EP-3368089-A1 | NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACID COMPLEXES | TRANSLATE BIO MA, INC. (US) | 2018-09-05 | — | — | EP | claimed |
| WO-2018119115-A1 | METHODS FOR AMELIORATING INFUSION REACTIONS | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2018-06-28 | — | — | WO | claimed |
| EP-2770057-A1 | Silencing of CSN5 gene expression using interfering RNA | Protiva Biotherapeutics Inc. (CA) | 2014-08-27 | — | — | EP | claimed |
| EP-2281041-B1 | SILENCING OF CSN5 GENE EXPRESSION USING INTERFERING RNA | PROTIVA BIOTHERAPEUTICS INC (CA) | 2014-07-02 | — | — | EP | claimed |
| EP-2449106-A1 | COMPOSITIONS AND METHODS FOR SILENCING APOLIPOPROTEIN B | Protiva Biotherapeutics Inc. (CA) | 2012-05-09 | — | — | EP | claimed |
| EP-2281041-A2 | SILENCING OF CSN5 GENE EXPRESSION USING INTERFERING RNA | Protiva Biotherapeutics Inc. (CA) | 2011-02-09 | — | — | EP | claimed |
| EP-2279254-A1 | NOVEL LIPID FORMULATIONS FOR NUCLEIC ACID DELIVERY | Protiva Biotherapeutics Inc. (CA) | 2011-02-02 | — | — | EP | claimed |
| WO-2011000108-A1 | COMPOSITIONS AND METHODS FOR SILENCING APOLIPOPROTEIN B | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2011-01-06 | — | — | WO | claimed |
| WO-2009129319-A2 | SILENCING OF CSN5 GENE EXPRESSION USING INTERFERING RNA | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2009-10-22 | — | — | WO | claimed |
| WO-2009127060-A1 | NOVEL LIPID FORMULATIONS FOR NUCLEIC ACID DELIVERY | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2009-10-22 | — | — | WO | claimed |
| EP-1948674-A1 | MODIFIED SIRNA MOLECULES AND USES THEREOF | Protiva Biotherapeutics Inc. (CA) | 2008-07-30 | — | — | EP | claimed |
| WO-2007051303-A1 | MODIFIED siRNA MOLECULES AND USES THEREOF | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2007-05-10 | — | — | WO | claimed |